Targeting glioma-initiating cells via the tyrosine metabolic pathway
作者： Daisuke Yamashita , Joshua D. Bernstock , Galal Elsayed , Hirokazu Sadahiro , Ahmed Mohyeldin
DOI: 10.3171/2019.11.JNS192028
关键词:
摘要: OBJECTIVE Despite an aggressive multimodal therapeutic regimen, glioblastoma (GBM) continues to portend a grave prognosis, which is driven in part by tumor heterogeneity at both the molecular and cellular levels. Accordingly, herein the authors sought to identify metabolic differences between GBM tumor core cells and edge cells and, in so doing, elucidate novel actionable therapeutic targets centered on tumor metabolism. METHODS Comprehensive metabolic analyses were performed on 20 high-grade glioma (HGG) tissues …
scilit.net参考文章(41)
Alan C. Aisenberg, Baltazar Reinafarje, Van R. Potter, STUDIES ON THE PASTEUR EFFECT Journal of Biological Chemistry. ,vol. 224, pp. 1099- 1113 ,(1957) , 10.1016/S0021-9258(18)65000-8
Grace Medes, Bernice Friedmann, Sidney Weinhouse, Fatty acid metabolism. VIII. Acetate metabolism in vitro during hepatocarcinogenesis by p-dimethylaminoazobenzene. Cancer Research. ,vol. 16, pp. 57- 62 ,(1956)
則雄 荒木, What's going on 放射線 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. N Engl J Med. 2005; 352: 987-96. PMID: 15758009.--神経膠腫に対する治療として、放射線治療とテモゾロマイドの併用が世界的な標準的治療となりうることを示唆する論文 Mebio oncology. ,vol. 3, pp. 132- 134 ,(2006)
Joanna Triscott, Mary Rose Pambid, Sandra E. Dunn, Concise Review: Bullseye: Targeting Cancer Stem Cells to Improve the Treatment of Gliomas by Repurposing Disulfiram Stem Cells. ,vol. 33, pp. 1042- 1046 ,(2015) , 10.1002/STEM.1956
Richard E. Kast, Georg Karpel-Massler, Marc-Eric Halatsch, CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide. Oncotarget. ,vol. 5, pp. 8052- 8082 ,(2014) , 10.18632/ONCOTARGET.2408
Jinkuk Kim, In-Hee Lee, Hee Jin Cho, Chul-Kee Park, Yang-Soon Jung, Yanghee Kim, So Hee Nam, Byung Sup Kim, Mark D. Johnson, Doo-Sik Kong, Ho Jun Seol, Jung-Il Lee, Kyeung Min Joo, Yeup Yoon, Woong-Yang Park, Jeongwu Lee, Peter J. Park, Do-Hyun Nam, Spatiotemporal Evolution of the Primary Glioblastoma Genome Cancer Cell. ,vol. 28, pp. 318- 328 ,(2015) , 10.1016/J.CCELL.2015.07.013
S. Zhao, Y. Lin, W. Xu, W. Jiang, Z. Zha, P. Wang, W. Yu, Z. Li, L. Gong, Y. Peng, J. Ding, Q. Lei, K.-L. Guan, Y. Xiong, Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α Science. ,vol. 324, pp. 261- 265 ,(2009) , 10.1126/SCIENCE.1170944
Ichiro Nakano, Stem cell signature in glioblastoma: therapeutic development for a moving target. Journal of Neurosurgery. ,vol. 122, pp. 324- 330 ,(2015) , 10.3171/2014.9.JNS132253
Rebecca A. Burrell, Nicholas McGranahan, Jiri Bartek, Charles Swanton, The causes and consequences of genetic heterogeneity in cancer evolution. Nature. ,vol. 501, pp. 338- 345 ,(2013) , 10.1038/NATURE12625
Manmeet S Ahluwalia, Carol Patton, Glen Stevens, Tanya Tekautz, Lilyana Angelov, Michael A Vogelbaum, Robert J Weil, Sam Chao, Paul Elson, John H Suh, Gene H Barnett, David M Peereboom, None, Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas Journal of Neuro-oncology. ,vol. 102, pp. 317- 321 ,(2011) , 10.1007/S11060-010-0325-3